MediciNova, Inc. (Nasdaq: MNOV) reported positive preliminary results from a Phase II clinical trial evaluating MN-221 in patients with moderate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE